QLT Photofrin lung cancer use recommended by advisory committee; broad indication rejected.
QLT PHOTOFRIN MICROINVASIVE LUNG CANCER INDICATION RECOMMENDATION would give the company an entry to the lung cancer therapy market. FDA's Oncologic Drugs Advisory Committee voted Sept. 18 that Photofrin (photodynamic porfimer) should be approved for treatment of microinvasive non-small cell lung cancer in patients for whom surgery and radiotherapy are not indicated. The committee, however, unanimously voted against a wider claim for reduction of obstruction and palliation of symptoms in endobronchial non-small cell lung cancer.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth